BACKGROUND

Rosacea refers to chronic diseases in which the redness of the facial skin can bother patients over many years. Newly formed vessels lead to functional insufficiency of peripheral circulation, impair trophicity of the epidermis and derma, cause dystrophic changes in collagen fibers and pilosebaceous apparatus with inflammatory response. Study of mechanisms for maintaining stability of the vascular tone has revealed a disturbance in the balance between the Ang-1/Ang-2 angiopoietins ratio and their association with the TIE-2 receptor. Angiopausin is able to restore the existing imbalance and stop the neoformation of derma vessels. Angiopausin at 6% concentration is included in the content of new concentrate and is used for correction of chronic redness in rosacea.

OBJECTIVE

To study the efficacy of monotherapy using angiopausin concentrate in patients with erythematotelangiectatic and papulopustular rosacea subtypes.

MATERIAL AND METHODS

We observed 17 women aged 34—63 years (mean age 51.0±1.9 years). All patients used the concentrate twice a day for 8 weeks. Examination included questionnaire survey, photography, mexametry and corneometry.

RESULTS

Questionnaire survey of patients before and after treatment has shown absence of the drug’s irritant effect. Study of the functional parameters of the skin has revealed a reduction in erythema, melanin content and increased hydration of the stratum corneum on the face after 8 weeks.

CONCLUSION

The angiopausin concentrate for 2 months of rosacea treatment contributes to reduction of newly formed vessels, is well tolerated, improves the appearance of patients, therefore it can be recommended for practical use by dermatologists and cosmetologists.